Novartis releases new data for innovative rare kidney disease treatment
Data from the pre-specified interim analysis of Fabhalta® (iptacopan) indicate a statistically significant reduction in proteinuria reduction.
List view / Grid view
Data from the pre-specified interim analysis of Fabhalta® (iptacopan) indicate a statistically significant reduction in proteinuria reduction.
On World Kidney Day 2024, Dr Marshall Fordyce, CEO of Vera Therapeutics explores the challenges of treating kidney disease and shares why the company’s lead candidate could become the first self-administered B-cell modulation therapy.
Adopting IoT systems as a pharmaceutical company can provide many opportunities but achieving success can be difficult. James Steiner explains how to effectively integrate IoT solutions into pharma.
The licence extension submission for Invokana and Vokanamet has been accepted by the EMA.
Immunotherapy drug plus targeted agent provided better progression-free survival and shrank tumors in more patients than standard one-drug treatment...
Acidosis related to use of metformin seen only in those with severely decreased kidney function...
The ability to quantify the extent of kidney damage and predict the life remaining in the kidney is now possible using a computer model based on artificial intelligence...
A team of researchers set out to discover the disease pathways of a rare genetic kidney disease and consequently found a compound that stops the disease in its tracks.
Researchers have presented promising results from a clinical trial of the experimental drug baricitinib in people with diabetic kidney disease...